These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27194675)

  • 1. First reported association of chronic lymphocytic leukaemia and interstitial granulomatous dermatitis.
    Riaz IB; Kamal MU; Segal RJ; Anwer F
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27194675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Nasr SH; Shanafelt TD; Hanson CA; Fidler ME; Cornell LD; Sethi S; Chaffee KG; Morris J; Leung N
    Ann Diagn Pathol; 2015 Jun; 19(3):130-6. PubMed ID: 25795422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
    Gentile M; Zirlik K; Ciolli S; Mauro FR; Di Renzo N; Mastrullo L; Angrilli F; Molica S; Tripepi G; Giordano A; Di Raimondo F; Selleri C; Coscia M; Musso M; Orsucci L; Mannina D; Rago A; Giannotta A; Ferrara F; Herishanu Y; Shvidel L; Tadmor T; Scortechini I; Ilariucci F; Murru R; Guarini A; Musuraca G; Mineo G; Vincelli I; Arcari A; Tarantini G; Caparrotti G; Chiarenza A; Levato L; Villa MR; De Paolis MR; Zinzani PL; Polliack A; Morabito F
    Eur J Cancer; 2016 Jun; 60():154-65. PubMed ID: 27127905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
    Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
    [No Abstract]   [Full Text] [Related]  

  • 6. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
    Eren R; Suyanı E
    Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
    Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
    Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab.
    Ghia P; Barnes G; Yang K; Tam CS; Robak T; Brown JR; Kahl BS; Tian T; Szeto A; Paik JC; Shadman M
    Curr Med Res Opin; 2023 Nov; 39(11):1505-1511. PubMed ID: 37752878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
    Špaček M; Obrtlíková P; Hrobková S; Cmunt E; Karban J; Molinský J; Šimkovič M; Mociková H; Mohammadová L; Panovská A; Novák J; Trněný M; Smolej L; Doubek M
    Leuk Res; 2019 Apr; 79():17-21. PubMed ID: 30797139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
    Robak T; Hellmann A; Kloczko J; Loscertales J; Lech-Maranda E; Pagel JM; Mato A; Byrd JC; Awan FT; Hebart H; Garcia-Marco JA; Hill BT; Hallek M; Eisenfeld AJ; Stromatt SC; Jaeger U
    Br J Haematol; 2017 Feb; 176(4):618-628. PubMed ID: 27977057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukaemia cutis after starting bendamustine: cause or coincidence?
    Mawri S; Nabi S; Jallad B; Won J
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26392439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
    Ames PR; Merashli M; Gentile F
    Eur J Immunol; 2019 Jun; 49(6):969-970. PubMed ID: 30893471
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
    Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
    Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.
    Cramer P; Fraser G; Santucci-Silva R; Grosicki S; Dilhuydy MS; Janssens A; Loscertales J; Rule S; Goy A; Traina S; Chan EKH; Diels J; Sengupta N; Mahler M; Salman M; Howes A; Chanan-Khan A
    Leuk Lymphoma; 2018 Sep; 59(9):2075-2084. PubMed ID: 29295653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combo Therapy Effective for Relapsed CLL.
    Cancer Discov; 2015 Jul; 5(7):OF8. PubMed ID: 26034053
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Soumerai JD; Davids MS; Werner L; Fisher DC; Armand P; Amrein PC; Neuberg D; Hochberg EP; Brown JR; Abramson JS
    Leuk Lymphoma; 2019 Dec; 60(12):2931-2938. PubMed ID: 31074316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal infiltrate by a plasmocytoïd chronic B lymphocytic leukaemia and renal failure: a rare occurrence in nephropathology. A case report and review of the literature].
    Aymard B; Beghoura R; Molina TJ
    Nephrol Ther; 2011 Nov; 7(6):479-87. PubMed ID: 21439927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.